Artificial Pancreas Device System Market

Artificial Pancreas Device System Market Overview (2022 to 2032)

[250 Pages Report] During the forecast period, the artificial pancreas device system market is expected to advance at a rapid pace with a CAGR of 18.2%.

The soaring incidence of diabetes, intense R&D efforts by players in the industry, and growing adoption for automated systems for glycemic control are the contributing factors growth of the market. Artificial pancreas device systems (APDS) regulate blood glucose levels in diabetic patients, and industry participants are conducting numerous studies to improve diabetes management.

These devices are much less invasive and thus widely used by patients. The growing geriatric population, rising diabetes incidence, and rising obesity prevalence are all driving artificial pancreas device system market growth.

Bionic Pancreas system, technological advancements such as in-home use of Bionic Pancreas system is also expected to create significant opportunities for expansion in the near future. Furthermore, increased awareness of APDS and their use has resulted in artificial pancreas device system market growth in both developed and developing countries.

APDS can eliminate the need for frequent sugar level checks. Furthermore, increased global teleconsultancy activity for follow-up and routine check-ups during the pandemic is likely to boost artificial pancreas device system market growth for point-of-care technologies such as APDS. As a result, the trends are expected to have a significant impact on the adoption of APDS in the coming years.

One of the key factors driving the artificial pancreas device system market growth is the rising prevalence of diabetes due to ageing, obesity, and an unhealthy lifestyle. One of the most important factors driving the expansion of the artificial pancreas device system market artificial pancreas device system market is the rising prevalence of diabetes due to ageing, obesity, and an unhealthy lifestyle.

The threshold suspended device system helps to reverse or lessen the severity of a dangerous drop in blood glucose level (hypoglycaemia) by temporarily suspending insulin delivery when the glucose level falls to or approaches a low glucose threshold. These are also known as low glucose suspends systems.

The regulation of glucose in diabetic patients is critical for improved health outcomes. As a result, threshold suspended device systems play an important role in hypoglycaemia management. Product innovations, increased product approvals, and partnerships and collaborations by key players all contribute to artificial pancreas device system market growth.

The United States dominated the artificial pancreas device system market, accounting for 88.50% of the total. High per capita income and rising healthcare spending are two key factors driving the global artificial pancreas device system market. Furthermore, smart device adoption and technological advancements such as the use of AI and data analytics are propelling industry growth. According to the International Diabetes Federation, one out of every eight adults has impaired blood glucose tolerance. During the forecast period, this ratio is expected to rise even further.

North America controlled the artificial pancreas device system market and had the highest revenue share. The region is also expected to be driven by rising obesity rates, the presence of efficient reimbursement policies, and increased awareness of advanced diabetes management technologies.

Additionally, the presence of prominent players, high treatment costs, technological advancement, and product launches are expected to propel the regional market. Furthermore, the growing diabetic population has prompted private and public organisations to invest in diabetes research. These factors are expected to increase APDS adoption in the region.

To strengthen their market position, key artificial pancreas device system market players are implementing strategies such as mergers and acquisitions, partnerships, and the launch of new technologically advanced products and services. They are heavily investing in R&D activities in order to produce technologically advanced products.

Medtronic, for example, received CE-Mark for its MiniMed 780G in June 2020. The device automatically adjusts basal insulin rates every five minutes and is appropriate for diabetic patients aged 7 to 80. Similarly, the FDA in the United States approved a next-generation hybrid closed-loop insulin delivery system for children aged 2 to 6 years with type 1 diabetes in September 2020.

DexCom, Inc. acquired Type Zero Technologies, Inc., a company that invented a system that could monitor and regulate insulin delivery from insulin pumps, thereby trying to position itself in the artificial pancreas technology market and raising the arificial pancreas device systems.

Attributes	Details
Artificial Pancreas Device System Market CAGR	18.2%
Artificial Pancreas Device System Market (2025)	USD 2.1 Billion

Sales of artificial pancreas device systems are expected to rise as they are used in the treatment of Type 1 diabetes, which requires multiple doses of insulin in a day and all-round the year and with rising diabetes cases across the globe.

In addition to this, demand for artificial pancreas device systems rises as it plays a crucial role in glucose control in diabetic patients for a better health outcome.

Control algorithm software in an external controller performs mathematical calculations to send dosing instructions to the insulin infusion pumps or computer and this feature likely drives the demand for artificial pancreas device systems.

Demand for artificial pancreas device systems is also expected to be fuelled by rising investments in R&D activities by major players to expand their artificial pancreas device system market share.

Furthermore, the increased demand for automated systems that control glucose levels due to their flexibility, accuracy, and ease of use drives the sales of artificial pancreas device systems in coming years.

Soaring demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also fuelling the sales of artificial pancreas device systems.

Various technological advancements, such as the development of software-based wireless systems integrated with automated controls, are also contributing to the higher demand for artificial pancreas device systems.

Furthermore, an increase in the demand for computerised glycemic control systems, the presence of a large population of children and elderly within the target customer group is propelling the sales of artificial pancreas device systems.

Demand for artificial pancreas device systems spikes as diabetes management technologies, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems, have advanced in recent years.

CGM advancements elicited a paradigm shift in the management of type 1 diabetes which is anticipated to bring about huge sales of artificial pancreas device systems, in turn, propelling the artificial pancreas device system market growt

What are the Key Influential Factors in the Artificial Pancreas Device System Market?

The Food and Drug Administration (FDA) is collaborating with private and government research institutions to improvise clinical studies and accelerate the development and demand for artificial pancreas device systems.

The FDA released a document on requirements of clinical studies and premarket approval applications for the production of artificial pancreas device systems. This will encourage the manufacturers to expand their artificial pancreas device system market share.

These devices cater to the need of calibrating the continuous glucose monitor at equal intervals and drive the demand for artificial pancreas device systems.

Also, sales of artificial pancreas device systems spike as the continuous glucose monitoring sensors are subjected to biofouling and fibrosis when they are placed subcutaneously which alters the productivity of sensors.

The FDA has identified issues in the components and software of insulin infusion pumps. The insulin used currently in the artificial pancreas device systems takes a longer duration of time to completely absorb.

Such factors related to artificial pancreas device systems could potentially hamper the demand for artificial pancreas device systems and the growth of the global artificial pancreas device system market.

What is the Region-wise Outlook of the Artificial Pancreas Device System Market?

Depending on geographic regions, the global Artificial Pancreas Device System market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan, and Middle East & Africa.

During the forecast period, Asia Pacific is expected to grow the fastest and elicit greater demand for artificial pancreas device systems.

Sales of artificial pancreas device systems are on the rise as well on account of changes in lifestyle, genetic modification, urbanisation, aging, etc.

Diabetes incidences are expected to rise during the forecast period in the region, in turn, supporting artificial pancreas device system market growth and increasing the demand for artificial pancreas device systems.

India, China, the USA, Indonesia, Pakistan, and Japan are the top six countries with the highest number of estimated cases of diabetes and large artificial pancreas device system market share.

As a result, the Asia Pacific and North America are anticipated to be the potential markets for the global artificial pancreas device system market players.

Europe is also expected to witness high sales of artificial pancreas device systems due to the presence of sophisticated healthcare infrastructure, high levels of patient awareness, and relatively higher levels of healthcare expenditure.

Furthermore, funds provided by the government to improve treatment quality are encouraging industry players and researchers to bring in new technology thereby surging the demand for artificial pancreas device systems.

Who are the Major Players in the Artificial Pancreas Device System Market?

Some of the key market players in the global artificial pancreas device system market are Pancreum, LLC, Medtronic, Inc., and JDRF.

In the near future, the global artificial pancreas device system manufacturers are likely to develop products that will not only monitor but also adjust the blood glucose levels rapidly without the need for intervention of the patient.

Such steps are anticipated to consolidate their position in the market by enlarging their artificial pancreas device system market share and the same augments the sales of artificial pancreas device systems.

The major players are pursuing a variety of strategies, including R&D investment, collaborations, and acquisitions in order to expand their artificial pancreas device system market share.

DexCom, Inc. acquired Type Zero Technologies, Inc., a company that designed a system to manage and regulate insulin delivery from insulin pumps, thereby positioning itself in the artificial pancreas technology market and this also raises the arificial pancreas device systems.

Scope Of Report

Report Attributes	Details
Growth rate	CAGR of 18.2% from 2022 to 2032
Base year for estimation	2021
Historical data	2015 to 2020
Forecast period	2022 to 2032
Quantitative units	Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032
Report coverage	Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered	Product, application, region
Regional scope	North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand
Country scope	USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa
Key companies profiled	Pancreum, LLC; Medtronic, Inc. and JDRF; Johnson & Johnson; Beta Bionics, Inc.; Tandem Diabetes Care and others.
Customization scope	Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.

Key Segments

By Device Type:

• Threshold Suspended Device System
• Control to Range (CTR) System
• Control to Target (CTT) System

By Region:

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

Frequently Asked Questions

What is the Growth Outlook for Artificial Pancreas Device System Market?

The market is likely to register a CAGR of 18.2% through 2032.

What is the Current Valuation of the Artificial Pancreas Device System Market?

The market is currently valued at US$ 2.1 Bn in 2025.

Which is the Leading Region in the Market?

North America is likely to be a leading market during the forecast period.